Mukhametov, U.F.,
Lyulin, S.V.,
Borzunov, D.Y.,
Gareev, I.F.,
Beylerli, O.A.,
Sufianov, A.A. (2022) to ectopic bone formation in soft tissues. Although the
molecular mechanism of HO is not fully understood
Tyurin, Anton,
Merkuryeva, Elena,
Zaripova, Aliya,
Markova, Tatyana,
Nagornova, Tatyana,
Dantsev, Ilya,
Nadyrshina, Dina,
Zakharova, Ekaterina,
Khusainova, Rita (2022) , a clinical and genetic analysis of 12 cases with
molecularly confirmed OI type V from 12 unrelated
Изменения иммунной системы в патогенезе нейрофиброматоза 1-го типа, a promising direction is NF1
therapy with STAT3 inhibitors and immune checkpoint inhibitors
Ahmad, S.,
Abbas, M.,
Ullah, M.F.,
Aziz, M.H.,
Beylerli, O.,
Alam, M.A.,
Syed, M.A.,
Uddin, S.,
Ahmad, A. (2022) suppression of EMT. NKILA is also a
target of natural anticancer compounds. Given the importance of NF-κB as a